Alembic Pharmaceuticals expands strategic collaboration with DifGen Pharmaceuticals for its US complex generics portfolio
Alembic Pharmaceuticals announced on 4 November 2026 the expansion of its strategic collaboration with DifGen Pharmaceuticals to expand its complex generics portfolio in the US.
By ScoutQuest · · 1 min read
- Announcement date
- 4 November 2026
- Collaboration scope
- expand its complex generics portfolio in the US
- Portfolio opportunities
- open FTF opportunities, potential Day 1 launches and products with limited expected competition
- Release
- Deal / acquisition
🔬 The portfolio includes open FTF opportunities, potential Day 1 launches and products with limited expected competition, the company says.
📌 Managing Director Pranav Amin says the collaboration is a capital efficient way to deepen Alembic's pipeline and to gain access to US manufacturing capabilities.
🏭 The expanded collaboration builds on an existing relationship that includes a joint venture in Canada, the company says.
Also from Alembic Pharmaceuticals
Alembic Pharmaceuticals submits audio recording of 4th November, 2026 post results conference call
4 Nov 2026
Alembic Pharma reported strong Q2 results with revenue up 36%, profit up around 81% and sharp improvement in EBITDA margins, driven by US formulations growth
4 Nov 2026
Updated contact details of KMP authorised to decide materiality and make disclosures
4 Nov 2026
More numbers
- Products in DifGen collaboration portfolio20+
- Aggregate reference market, DifGen portfolio~US$5 billion
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.